BioSpace News Archive

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that Salem Health Hospitals & Clinics has partnered with Omnicell to improve safety and efficiency in their medication management processes through the Company’s automation and intelligence solutions at their flagship Salem Hospital, in Salem, Ore.

Relmada Therapeutics, Inc. (OTCQB: RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company’s common stock has been approved for listing on The Nasdaq Capital Market

Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that they have completed Phase I of their In-Life dose escalation study.

Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value.

The only behavioral health company to make the prestigious list, Tridiuum earns a top spot thanks to impressive revenue growth

Agreement strengthens ProciseDx proprietary diagnostic platform with broad applications in disease diagnosis and management.

Over 9,000 newly Certified PAs enter the profession, helping to alleviate provider shortages

ADAM, a 3D bone printing project that has already secured partnerships with ARMI, Stanley Black & Decker, and Big Pharma, is just months away from launching the first clinical trials.

SAB Members Bring Cancer Immunotherapy and Clinical Trial Experience to the Development of Bolt’s Immune-stimulating Antibody Conjugate Technology

Montefiore Einstein Doctor Receives NIH Grant to Expand Newborn Screening and Improve Diagnosis and Access to Treatment [08-October-2019] NEW YORK , Oct. 8, 2019 /PRNewswire/ -- Pediatric genetic expert Dr. Melissa Wasserstein has been awarded $3.2 million from the National Institutes of Health (NIH) to conduct the most expansive consented pilot newborn screenin